Ardelyx presents real‑world evidence that XPHOZAH lowers serum phosphate in dialysis patients
+1 new source since this summary was written
Ardelyx reported data from a real‑world analysis of more than 1,400 adult dialysis patients who started XPHOZAH, either alone or with a single phosphate binder. Over a six‑month follow‑up, average serum phosphate fell by 0.80 to 1.55 mg/dL. Between 16% and 41% of patients achieved a level below 5.5 mg/dL, and 60%‑70% stayed on therapy through day 180.
Why it matters
The reductions demonstrate XPHOZAH’s effectiveness in routine clinical practice, which may support broader adoption among dialysis providers. Continued therapy rates of 60%‑70% suggest acceptable tolerability, influencing prescribing decisions.
Key facts
- 1The analysis included more than 1,400 adults on dialysis with hyperphosphatemia who initiated XPHOZAH. stocktitan.net
- 2Adjusted mean serum phosphate reductions at month six ranged from 0.80 mg/dL to 1.55 mg/dL. stocktitan.net
- 3The probability of reaching a serum phosphate level below 5.5 mg/dL was between 16% and 41% at six months. tradingview.com
- 4Between 60% and 70% of patients remained on XPHOZAH therapy at day 180. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.